| scholarly article | Q13442814 |
| P356 | DOI | 10.1191/096120399678847380 |
| P698 | PubMed publication ID | 10025601 |
| P50 | author | Iain McInnes | Q41687181 |
| Susan Manzi | Q111603941 | ||
| P2093 | author name string | J C Davis | |
| H Austin | |||
| D T Boumpas | |||
| J H Klippel | |||
| C Yarboro | |||
| J Balow | |||
| V G Hale | |||
| D Averthelyi | |||
| D Sinicropi | |||
| J Rairie | |||
| P433 | issue | 1 | |
| P921 | main subject | lupus nephritis | Q1621830 |
| P304 | page(s) | 68-76 | |
| P577 | publication date | 1999-01-01 | |
| P1433 | published in | Lupus | Q6704846 |
| P1476 | title | Recombinant human Dnase I (rhDNase) in patients with lupus nephritis | |
| P478 | volume | 8 |
| Q39602530 | 5'-Phosphate oligodeoxynucleotides enhance the phosphodiester-CpG DNA-induced inflammatory response in macrophages |
| Q35951268 | A subset of patients with systemic lupus erythematosus fails to degrade DNA from multiple clinically relevant sources |
| Q35167886 | Acquired loss of renal nuclease activity is restricted to DNaseI and is an organ-selective feature in murine lupus nephritis |
| Q39166302 | An emerging role for neutrophil extracellular traps in noninfectious disease |
| Q35334977 | Antigen is required for maturation and activation of pathogenic anti-DNA antibodies and systemic inflammation |
| Q38773170 | Antitumor Effects of Systemic DNAse I and Proteases in an In Vivo Model |
| Q38666678 | At the Bedside: Neutrophil extracellular traps (NETs) as targets for biomarkers and therapies in autoimmune diseases. |
| Q36618394 | Autoimmunity versus tolerance: can dying cells tip the balance? |
| Q38926368 | Cell death in the pathogenesis of systemic lupus erythematosus and lupus nephritis |
| Q64075227 | Cell-Free DNA as a Biomarker in Autoimmune Rheumatic Diseases |
| Q49992541 | Cell-free DNA: the role in pathophysiology and as a biomarker in kidney diseases |
| Q37872038 | Chromatin as a target antigen in human and murine lupus nephritis |
| Q37892917 | Clearing the complexity: immune complexes and their treatment in lupus nephritis |
| Q91672607 | Clinical Implications of Excessive Neutrophil Extracellular Trap Formation in Renal Autoimmune Diseases |
| Q58620990 | DNA as a self-antigen: nature and regulation |
| Q41247932 | DNaseI protects against Paraquat-induced acute lung injury and pulmonary fibrosis mediated by mitochondrial DNA. |
| Q88678770 | Degradation of Extracellular DNA by DNase1 Significantly Reduces Testicular Damage After Testicular Torsion in Rats |
| Q37690679 | Degradation of neutrophil extracellular traps co-varies with disease activity in patients with systemic lupus erythematosus |
| Q34108832 | Dehydroepiandrosterone and biologics in the treatment of systemic lupus erythematosus |
| Q21195358 | Disturbances of apoptotic cell clearance in systemic lupus erythematosus |
| Q91543803 | Dnase1-deficient mice spontaneously develop a systemic lupus erythematosus-like disease |
| Q73943065 | Dnase1l3 deficiency in lupus-prone MRL and NZB/W F1 mice |
| Q39407928 | Dnases in health and disease |
| Q44328122 | Effect of recombinant human deoxyribonuclease on the expression of cell adhesion molecules of thawed and processed cord blood hematopoietic progenitors |
| Q92860794 | Extracellular DNA traps in inflammation, injury and healing |
| Q44397077 | Extracorporeal immunoadsorption of antibodies against the VRT-101 laminin epitope in systemic lupus erythematosus: a feasibility evaluation study |
| Q42801296 | Features of systemic lupus erythematosus in Dnase1-deficient mice |
| Q73158589 | HLA class II antigens associated with lupus nephritis in Italian SLE patients |
| Q57689077 | Immunosuppressive treatment for proliferative lupus nephritis |
| Q33418811 | Impaired DNase1-mediated degradation of neutrophil extracellular traps is associated with acute thrombotic microangiopathies. |
| Q39328138 | In Vivo Role of Neutrophil Extracellular Traps in Antiphospholipid Antibody-Mediated Venous Thrombosis |
| Q28082543 | Intrapleural tissue plasminogen activator and deoxyribonuclease therapy for pleural infection |
| Q28199068 | Lupus and desoxyribonuclease |
| Q47111503 | Lupus nephritis progression in FcγRIIB-/-yaa mice is associated with early development of glomerular electron dense deposits and loss of renal DNase I in severe disease |
| Q38113421 | Lupus nephritis: enigmas, conflicting models and an emerging concept |
| Q57089568 | Lupus, DNase and defective disposal of cellular debris |
| Q39019253 | NETosis provides the link between activation of neutrophils on hemodialysis membrane and comorbidities in dialyzed patients |
| Q34323566 | NETs: the missing link between cell death and systemic autoimmune diseases? |
| Q35090145 | Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases |
| Q36693228 | Neutrophil Extracellular Traps Promote the Development and Progression of Liver Metastases after Surgical Stress |
| Q38234749 | Neutrophil extracellular traps in cancer progression |
| Q49570630 | Neutrophils and neutrophil extracellular traps in the liver and gastrointestinal system |
| Q33893393 | New therapies for systemic lupus erythematosus |
| Q34481499 | Novel approaches in the treatment of lupus nephritis |
| Q55101116 | Obesity-induced Endothelial Dysfunction is Prevented by Neutrophil Extracellular Trap Inhibition. |
| Q91312483 | PAD4-dependent NETs generation are indispensable for intestinal clearance of Citrobacter rodentium |
| Q36966870 | Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus |
| Q46301200 | Pharmacologic Protection of Mitochondrial DNA Integrity May Afford a New Strategy for Suppressing Lung Ischemia-Reperfusion Injury |
| Q47690527 | Pharmacological targeting of peptidylarginine deiminase 4 prevents cancer-associated kidney injury in mice |
| Q37510905 | Pharmacotherapy of systemic lupus erythematosus. |
| Q49605362 | Platelet-neutrophil interactions as drivers of inflammatory and thrombotic disease |
| Q33697979 | Renal Dnase1 Enzyme Activity and Protein Expression Is Selectively Shut Down in Murine and Human Membranoproliferative Lupus Nephritis |
| Q47863891 | Spatiotemporally Controlled Release of Rho-Inhibiting C3 Toxin from a Protein-DNA Hybrid Hydrogel for Targeted Inhibition of Osteoclast Formation and Activity |
| Q73730202 | Systemic lupus erythematosus |
| Q26746697 | Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway |
| Q37060593 | Targeting of the immune system in systemic lupus erythematosus |
| Q28085243 | The Role of Anti-DNA Antibodies in the Development of Lupus Nephritis: A Complementary, or Alternative, Viewpoint? |
| Q90613288 | The Role of Immune Checkpoint Receptors in Regulating Immune Reactivity in Lupus |
| Q34897103 | The in vivo expression of actin/salt-resistant hyperactive DNase I inhibits the development of anti-ssDNA and anti-histone autoantibodies in a murine model of systemic lupus erythematosus |
| Q89181533 | The role of neutrophil extracellular traps in rheumatic diseases |
| Q33904653 | The role of neutrophils and NETosis in autoimmune and renal diseases |
| Q90053693 | Therapeutic strategies for thrombosis: new targets and approaches |
| Q47157898 | Therapeutic targeting of extracellular DNA improves the outcome of intestinal ischemic reperfusion injury in neonatal rats |
| Q34731092 | Therapy of systemic lupus erythematosus: a look into the future |
| Q34074960 | Therapy of systemic lupus erythematosus: new agents and new evidence |
| Q24202572 | Treatment for lupus nephritis |
| Q78814998 | Treatment of lupus nephritis |
| Q74022703 | Treatment of systemic lupus erythematosus |
| Q35045914 | Triggers for anti-chromatin autoantibody production in SLE. |
| Q34680564 | Unintentional intramuscular administration of tPA/DNase for pleural infection |
Search more.